In October 2007, the FDA introduced that the labeling for all PDE5 inhibitors, together with tadalafil, requires a additional notable warning from the probable threat of unexpected hearing reduction as the results of post-marketing and advertising studies of momentary deafness linked to utilization of PDE5 inhibitors.[19]The ministry named various … Read More